Celltrion trials infliximab biosimilar in recovering COVID-1...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. 

Celltrion to develop coronavirus antibody and fast test

South Korea’s Celltrion has joined the many pharma companies fighting the COVID-19 coronavirus outbreak, saying it is working on an antibody-based antiviral and a self-testing diagnosis kit

Celltrion plans to launch a biosimilar each year for next de...

There are plenty of pharma companies outlining their strategies for the new decade this week at the JP Morgan Healthcare conference, and South Korea’s biosimilars specialist Celltrion was n

Celltrion gears up for subcutaneous infliximab launch in Eur...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a p

First Rituxan biosimilar Truxima set to make its debut in US

Celltrion/Teva's Herceptin biosimilar approved in US

The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US.